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CASE PRESENTATION
A 51-year-old Caucasian man was hospitalized because
of myalgia and fever. He had been suffering from
chronic rhinitis since the age of 18 years and from asthma
since the age of 45 years. Three months before
hospitalization, he had received an influenza vaccine. On
admission, he also complained of fatigue and paresthesias
involving the lower limbs, and reported the recent onset
of palpable purpura at both legs (Figure 1a). Laboratory
tests are summarized in Table 1. The patient’s HLA-DRB1
genotype was positive for *04–*07 alleles, both belonging
to the HLA-DRB4 gene. Chest computed tomography (CT)
scan was normal, whereas head CT showed diffuse sinusitis
(Figures 1c and d). Electroneurography disclosed
sensorimotor polyneuropathy with signs of axonal damage
affecting the right peroneal and left sural nerves. A biopsy
of the purpuric lesions was performed, and histology
showed leukocytoclastic vasculitis (Figure 1b). As an
antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis was suspected and urinary abnormalities
persisted, renal biopsy was performed. On light microscopy
(Figure 2), the biopsy specimen included 24 glomeruli,
3 of which were obsolescent. Segmental necrosis was
found in 30% of the glomeruli, whereas four showed
extracapillary proliferation. The tubulointerstitium,
arterioles, and venules were normal, with no eosinophilic
infiltration. Immunofluorescence showed no immune
deposits. Churg–Strauss syndrome (CSS) was diagnosed on
the basis of histological findings showing vasculitis and the
presence of asthma, eosinophilia, sinusitis, and
polyneuropathy. Prednisone therapy (initial dose 1mg/kg/
day) induced rapid symptom remission, normalization
of the eosinophil count, and urinary abnormalities.
Prednisone was stopped 9 months later but was resumed
soon after withdrawal because of relapsing asthma.
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DEFINITIONS AND CLASSIFICATION CRITERIA OF CSS
Churg–Strauss syndrome is characterized by small-vessel
vasculitis, eosinophil-rich inflammation, vascular and/or
extravascular granulomas, and peripheral eosinophilia
occurring in patients with asthma and often allergic rhinitis
or sinusitis.1 Since the seminal study by Churg and Strauss,2
who described the syndrome as a condition of ‘allergic
granulomatosis and angiitis,’ a number of definitions and
classification criteria have been proposed. The American
College of Rheumatology (ACR) criteria were established to
distinguish the individual forms of vasculitis from each
other; thus, they must be used for the classification and not
for the diagnosis of vasculitis, and should ideally be applied
only when histological evidence of vasculitis is available. The
ACR criteria for CSS include asthma, eosinophilia 410%,
peripheral neuropathy, pulmonary infiltrates, paranasal sinus
abnormalities, and extravascular eosinophils; the presence of
at least four of these six criteria yields a sensitivity of 85% and
a specificity of 99.7% for the classification of vasculitis as
CSS.3 The Chapel Hill consensus conference generated
mutually exclusive definitions for the different vasculitides,
and defined CSS as an ‘eosinophil-rich and granulomatous
inflammation involving the respiratory tract and necrotizing
vasculitis affecting small-to-medium-sized vessels, associated
with asthma and eosinophilia.’4
EPIDEMIOLOGY
The prevalence of CSS is 11–14/1,000,000 inhabitants and its
annual incidence is 2.7/1,000,000 patients.5 It frequently
occurs in patients aged 40–60 years, the mean age at diagnosis
beingB48 years;1 however, as asthma and allergic rhinitis or
sinusitis are frequent, and may precede the vasculitic mani-
festations of many years, there is often a delay between initial
symptoms and diagnosis. There is no clear gender pre-
dominance, ethnic predisposition, or familial clustering.
CLINICAL MANIFESTATIONS AND LABORATORY FINDINGS
The clinical course of CSS usually evolves through three phases:
the prodromic, ‘allergic’ phase, hallmarked by asthma, allergic
rhinitis, and sinusitis; the second, ‘eosinophilic’ phase, with
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peripheral eosinophilia and clinical features due to tissue
eosinophilic infiltration (for example, eosinophilic gastroenter-
itis); the third, also called ‘vasculitic,’ with manifestations of
necrotizing vasculitis (for example, peripheral neuropathy and
purpura).1
Churg–Strauss syndrome can involve almost any organ.
The frequencies of its clinical features are reported in
Table 2.6–8 Asthma precedes the systemic symptoms of a
mean of 8–12 years;9,10 it often has an adult onset and
may paradoxically improve when vasculitic symptoms
develop. In addition to typical nasal/paranasal sinus mani-
festations, purulent bloody nasal discharge and nasal
crusting may also occur, although they are more typical of
Wegener’s granulomatosis. Other otolaryngological mani-
festations include otitis media and sensorineural hearing
loss.10 Lung involvement shows two fairly distinct patterns
on CT: an ‘airway’ pattern, with bronchial wall thicken-
ing or dilatation, small centrilobular nodules and tree-in-
bud signs, and an ‘airspace’ pattern, with ground-glass
opacities, consolidation, and poorly defined infiltrates.
Airway and airspace patterns are, respectively, associated
with obstructive and restrictive pulmonary function test
results.11 Unlike in Wegener’s granulomatosis, CSS nodules
seldom cavitate.
Peripheral neuropathy, characterized by axonal damage
on electrophysiological studies, most frequently affects the
peroneal, median, tibial, and ulnar nerves.9,12 The small
bowel is more frequently involved than the large bowel, with
most cases showing eosinophilic gastroenteritis or ischemic
lesions.13
Renal disease is often an overlooked feature of CSS.
Although less frequent and severe than in the other ANCA-
associated vasculitides, renal manifestations occur in 25% of
CSS patients.14 The most typical picture is pauci-immune
focal and segmental necrotizing glomerulonephritis, with or
without crescents, which usually involve o50% of the
glomeruli. Tubulo-interstitial eosinophilic nephritis is found
only occasionally; a few patients have mesangial glomerulo-
nephritis or focal segmental sclerosis. Finally, obstructive
uropathy due to ureteral involvement has also been reported.
Renal disease is an adverse prognostic factor for CSS patients;
the largest study accurately assessing renal involvement
in CSS showed a (although not statistically significant)
higher 5-year mortality rate in patients with renal involve-
ment than in those without;14 previous studies also showed
that proteinuria 41 g/24 h was a particularly strong predictor
of mortality in CSS.1,9
Figure 1 |Clinical and imaging findings on admission to
hospital. (a) Purpura of the lower limbs. (b) Low-power
magnification appearance of a skin biopsy of the purpuric lesions
seen in panel a, showing an inflammatory infiltrate mainly
involving the dermal vessels (arrowheads) with aspects of
leukocytoclastic vasculitis. The epidermal epithelium is normal.
Hematoxylin and eosin staining, original magnification 4.
(c, d) Computed tomographic scans of the head showing diffuse
signs of sinusitis; an isodense and homogeneous tissue occupies
completely the right (black arrow) and partially the left
(arrowhead) maxillary sinuses; the nasal mucosa also appears
markedly thickened (white arrow). No bone erosions are evident.
(c) Axial and (d) coronal views.
Table 1 | Results of laboratory tests
On admission to hospital Normal values
White-cell count (cells/mm3) 23,000 4000–11,000
Eosinophils (%) 52 2–8
Erythrocyte sedimentation
Rate (mm/h)
40 2–30
C-reactive protein (mg/l) 11.2 0–5
Creatinine (mmol/l) 124 44–124
Urinalysis Dysmorphic hematuria
Proteinuria (mg/24 h) 960 o150
ANCA 1/80 (perinuclear pattern) Negative
Anti-MPO antibodies (EU/ml) 100 o6
ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase.
Figure 2 |Renal biopsy findings. (a) Segmental necrosis (arrow) in an otherwise normal glomerulus. Hematoxylin and eosin staining,
original magnification  40. (b) Glomerular extracapillary proliferation: part of the glomerulus is occupied by a cellular crescent (arrow),
which confines the capillary tuft against Bowman’s capsule. Masson’s trichrome staining, original magnification 40. (c) The tubules and
the interstitium do not show remarkable abnormalities. Masson’s trichrome staining, original magnification 40.
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Cardiac manifestations, often severe, include left ventri-
cular or global heart failure, conduction abnormalities,
myocardial infarction (due to coronary vasculitis), and
pericarditis.9
Laboratory tests show peripheral eosinophilia 41500 cells
per ml in B90% of patients;15 undetected eosinophilia
often results from oral corticosteroid treatment for asthma.
High C-reactive protein levels and sedimentation rates are
common, as well as inflammatory disease-related anemia.7
Total serum IgE levels are high in B90% of cases, but IgE
specific to common allergens is positive in o30%, thus
implying that putative unidentified allergens are involved in
CSS.15 ANCAs are positive using immunofluorescence
in 38% of the patients, 74–90% of whom have a peri-
nuclear-ANCA (P-ANCA) and o10% a cytoplasmic pattern
(C-ANCA);7,8 a few cases show ‘atypical’ patterns (Cþ P) or
C-ANCA without the usual interlobular accentuation
(‘C-ANCA atypical’).8 On ELISA, almost all P-ANCAs are
anti-myeloperoxidase, whereas C- or atypical ANCAs are either
anti-myeloperoxidase, anti-proteinase 3, or undetermined.8
HISTOPATHOLOGY
The typical histopathological elements of CSS are extra-
vascular granulomas, small-to-medium-sized-vessel vasculi-
tis, and tissue eosinophilia. Extravascular granulomas show a
center of necrotic eosinophils surrounded by palisading
lymphocytes and multinucleated giant cells.2,3 Vasculitis
involves arteries, arterioles, and, less frequently, venules,
and often includes eosinophil-rich infiltrates;3 it is charac-
terized by vessel wall fibrinoid necrosis and may or may not
be granulomatous.
These key features are concomitantly found in only a
minority of cases; in addition, some lesions underlie specific
histopathological abnormalities and specific sites commonly
lack eosinophilic infiltration. For instance, purpura is usually
due to leukocytoclastic vasculitis (without fibrinoid necrosis
or eosinophils), and pulmonary hemorrhage is due to
alveolar capillaritis (without granulomas).9 Eosinophilic
infiltrates are also rare in CSS glomerulonephritis.14 Simi-
larly, peripheral nerve histology shows epineural vasculitis
but almost never eosinophils.
Other affected sites have a broader range of histological
pictures.9 Gastrointestinal lesions may be characterized by
tissue eosinophilia, as in cases presenting with eosinophilic
gastroenteritis, or mesenteric vasculitis, which causes small-
or large-bowel ischemia; in some cases, granulomas, vascu-
litis, and tissue eosinophilia coexist.13 Cardiac lesions range
from eosinophilic coronary vasculitis to transmural eosino-
philic granulomatous myocarditis; pericarditis may also
occur, with pericardial biopsies often disclosing necrotizing
vasculitis and eosinophilic infiltrates.9 Lung manifestations
other than alveolar hemorrhage also encompass different
lesions, which in some cases are similar to those of eosino-
philic pneumonia, whereas in others they show granulomas
and necrotizing vasculitis; bronchial wall thickening is often
due to eosinophilic and lymphocytic infiltration.11
DISTINCT CLINICAL SUBSETS: THE ‘ANCA DICHOTOMY’
That CSS represents a spectrum of diseases rather than a
single entity had already been proposed by Churg and
Strauss, who reported ‘other allergic syndromes (Lo¨ffler,
Zuelzer, Silk) may represent the more benign forms of allergic
granulomatosis, while angiitis is its most malignant expres-
sion.’2 Two recent studies have shown that ANCAs may help
differentiate CSS subsets, as ANCA positivity is associated
with a higher frequency of renal involvement, peripheral
Table 2 | Frequencies of the main clinical manifestations of Churg–Strauss syndrome in three large series of patients
Keogh and Specks6 Sinico et al.8 Sable´-Fourtassou et al.7 Main clinical features by organ system
91 patients 93 patients 112 patients
Asthma 99% 96% 100%
Nasal and paranasal
sinus involvement
74% 77% 62% Rhinitis, sinusitis, nasal polyps
Lung involvement 58% 51% Infiltrates, 65%; pleural
effusion, 22%; alveolar
hemorrhage, 7%
Migratory pulmonary infiltrates, pleural
effusion, alveolar hemorrhage
Constitutional
symptomsa
NA 68% Weight loss, 8%; fever, 45%;
arthralgia, 37%; myalgia, 54%
Skin manifestations 57% 53% 52% Purpura, nodules, urticarial lesions
Peripheral nervous
system involvement
76% 65% 72% Mononeuropathy, mononeuropathy
multiplex, distal symmetric
polyneuropathy
Gastrointestinal
manifestations
31% 22% 32% Abdominal pain, digestive hemorrhage,
diarrhea
Kidney involvement 25% 27% 16% Urinary abnormalities, rapidly progressive
renal failure
Heart involvement Endomyocardial,
13%; pericardial, 8%
16% 35% Cardiomyopathy, pericarditis
Central nervous system
involvement
11% 14% 9% Cranial nerve palsy, cerebral infarction or
hemorrhage
NA, not available.
aConstitutional symptoms include weight loss, fever, fatigue, diffuse arthralgia, and myalgia.
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neuropathy, alveolar hemorrhage, and purpura (all manifes-
tations of necrotizing vasculitis), whereas ANCA negativity is
associated with heart and lung disease (other than alveolar
hemorrhage).7,8 Interestingly, histological signs of vasculitis
were more frequent in ANCA-positive than in ANCA-
negative patients.7 These findings suggest the presence of
two separate subsets, one ANCA associated, with features
of small-vessel vasculitis, and one ANCA negative, in which
organ damage is mainly mediated by eosinophilic infiltration.
It can be noted that this dichotomy has an immunogenetic
basis, as the frequency of the CSS-associated HLA-DRB4 gene
is higher in CSS patients with vasculitis symptoms.16
PATHOGENESIS
It has been shown that CSS is associated with the HLA-DRB4
gene and particularly with its HLA-DRB1*04 and *07
alleles.16 A restricted HLA repertoire points to an antigen-
driven, T-cell-dependent disease,16 a view supported by the
presence of T-cell clones with similar T-cell receptor
specificities in CSS patients.17
Both CD4þ and CD8þ T cells are found in CSS lesions,
and soluble interleukin (IL)-2-receptor serum levels (sugges-
tive of T-cell activation) are high in CSS patients. Peripheral
T-cell lines from CSS patients show a predominance
of CD4þ cells producing not only T-helper (Th)2 (for
example, IL-4, IL-13) but also Th1 cytokines (for example,
interferon-g (IFN-g)). In addition, peripheral mononuclear
cells secrete high levels of IL-5, which promotes eosinophil
activation and adhesion to endothelium.18 Variations in
the Th1/Th2 cytokine ratio potentially account for the
heterogeneous CSS phenotype, which can range from a
predominantly Th1-mediated granulomatous vasculitis to
Th2-mediated systemic hypereosinophilia.18
Eosinophils may cause tissue damage by releasing
cytotoxic granule proteins (for example, eosinophil cationic
and major basic protein) or by inducing apoptosis of target
cells,19 and can also function as antigen-presenting cells.18
Prolonged eosinophil survival may be regulated by T cells
through the CD95–CD95 ligand (CD95L) apoptotic pathway:
CSS peripheral lymphocytes exhibit a switch from the
membrane-bound CD95 isoform to its soluble splice variant,
which protects eosinophils and T cells themselves from
CD95L-mediated apoptosis; consequently, the T-cell–eosino-
phil crosstalk may promote both sustained eosinophilia and
T-cell clonal expansion.17
Endothelial cells also contribute to CSS eosinophilia by
producing eotaxin-3, a chemokine with strong chemotactic
activity on eosinophils; its serum levels correlate with the
degree of eosinophilia and disease activity in CSS patients.20
B cells can function as antigen-presenting cells and be
precursors of ANCA-producing plasma cells; ANCAs may
ultimately cause vasculitis through different mechanisms (for
example, neutrophil activation and reactive oxygen metabo-
lite production). The pathogenetic role of ANCAs in CSS is
uncertain, although their high frequency in CSS patients with
vasculitic manifestations strengthens the hypothesis that they
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T-cell activation–
expansion
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Tissue damage
ECP, MBP, ...
CD95–CD95L
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IL-5
IL-4, IL-13
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Figure 3 |Pathogenetic model proposed for Churg–Strauss syndrome, based on available experimental evidence. Hypothetical
allergens or antigens may be uptaken by antigen-presenting cells and presented to CD4þ T cells, leading to T-cell activation and
expansion. Antigen-presenting cells (which can be of different cell types, for example, dendritic cells, monocyte macrophages, and
eosinophils) have a restricted HLA repertoire and often express HLA-DRB4. Once activated, CD4þ T cells secrete IFN-g, which promotes
granulomatous inflammation, and also drive eosinophil activation and expansion through the secretion of IL-4, IL-5, and IL-13, or by means
of the CD95–CD95L pathway. Eosinophils mediate tissue damage mainly by secreting granule proteins such as ECP and MBP. Endothelial
cells may also contribute to tissue infiltration by eosinophils by releasing eotaxin-3, a chemokine with strong chemotactic activity on
eosinophils. B cells are also likely to play a pathogenetic role: activated on antigen encountering and ‘helped’ by T-helper 2 cytokines such
as IL-4 and IL-13, they may become mature plasma cells and then produce different autoantibodies, including ANCA, which may in turn
mediate vasculitis. ANCA, anti-neutrophil cytoplasmic antibodies; CD95L, CD95 ligand; ECP, eosinophilic cationic protein; IFN-g, interferon-g;
IL(-4, -5, -13), interleukin(-4, -5, -13); MBP, major basic protein; TCR, T-cell receptor.
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mediate vascular injury and inflammation.1 The efficacy of
B-cell-depleting agents in some refractory CSS cases further
supports a pathogenetic role of B cells.21
Finally, different agents may trigger CSS, such as allergens,
vaccinations, and drugs. Numerous reports showed a
temporal correlation between the use of anti-leukotrienes
for asthma and the development of CSS; however, these drugs
allow steroid tapering, which can unmask incomplete forms
of CSS.1 Figure 3 depicts an immunopathogenetic model
of CSS.
TREATMENT AND PROGNOSIS
Current views indicate that the treatment of CSS should be
tailored on the basis of patient prognosis. Five factors are
considered to be strong prognostic predictors (five-factor
score, FFS), namely, heart, gastro-intestinal, and central
nervous system involvement, proteinuria 41g /24 h, and
creatinine4140 mmol/l (each factor is given 1 point). Patients
with FFS¼ 0 should receive corticosteroids alone, whereas
those with FFSX1 should also receive cytotoxic agents (for
example, cyclophosphamide, CYC) as first-line therapy.1,22–25
High corticosteroid doses (usually 1 mg/kg/day of pre-
dnisone) are used as initial therapy, with corticosteroid pulses
before oral treatment in severe cases. Steroid tapering should
begin when acute-phase reactants or eosinophil counts
normalize. CYC is added to steroids also in the case of
steroid-resistant, steroid-dependent, or frequently relapsing
disease.1,22 As for the duration of induction therapy, it has
been shown that patients given CYC for 4–6 months have
higher relapse rates than those treated for 1 year.22 Once
remission is achieved, a switch from CYC to the less toxic
azathioprine is recommended. The duration of maintenance
therapy should be at least 6 months; however, steroids are
usually continued for asthma, which often persists despite
vasculitis remission. The therapeutic recommendations based
on FFS should be taken with caution and critically considered
case by case, as they carry the risk of overtreating patients
with minor complications (for example, proteinuria slightly
higher than 1 g/day) and, on the other hand, undertreating
those with severe disease manifestations (for example, severe
peripheral neuropathy).
Up to 10% of CSS patients are refractory to conventional
treatment. The anti-CD20 monoclonal antibody, rituximab,
has been effective in refractory CSS, also by inducing a
decrease in eosinophil counts, ANCA, and serum IL-5
levels.21 Mycophenolate mofetil has also been reported to
be effective.22 Other agents for refractory CSS include IFN-a,
whereas no evidence yet supports the use of anti-IL5 or anti-
IgE-antibodies; notably, CSS developed in asthmatic patients
receiving the anti-IgE, omalizumab, probably because this
allows (as do anti-leukotrienes) steroid tapering.1
The outlook of CSS is usually good. Remission can be
achieved in B90% of patients,22,24 but 35–74% of them
relapse; relapses are often heralded by increased peripheral
eosinophilia and usually respond to raised corticosteroid
doses or resumption of immunosuppressants.6,22,24
CONCLUSIONS
CSS has a heterogeneous clinical spectrum, ranging from a
predominantly eosinophilic/allergic disorder to systemic
vasculitis. ANCAs, being correlated with CSS vasculitic
manifestations, may help differentiate these clinical subsets.
Although CSS often responds to steroids and immuno-
suppressants, more selective therapeutic approaches are
needed to reduce exposure to immunosuppression and
for refractory cases. Future studies are warranted to
elucidate the genetic and immune-mediated pathogenetic
mechanisms.
ACKNOWLEDGMENTS
We thank Pietro Schianchi for his help in preparing the photographs,
Davide Martorana for performing HLA genotyping, Raimondo Boeri
for providing renal biopsy slides, and all of the members of the
Secondary and Primitive Vasculitis Study Group for their collaboration
in research and clinical management of Churg–Strauss syndrome
patients.
REFERENCES
1. Pagnoux C, Guilpain P, Guillevin L. Churg–Strauss syndrome. Curr Opin
Rheumatol 2007; 19: 25–32.
2. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and
periarteritis nodosa. Am J Pathol 1951; 27: 277–301.
3. Masi AT, Hunder GG, Lie JT et al. The American College of
Rheumatology 1990 criteria for the classification of Churg–Strauss
syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:
1094–1100.
4. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic
vasculitides. Proposal of an international consensus conference. Arthritis
Rheum 1994; 37: 187–192.
5. Mahr A, Guillevin L, Poissonnet M et al. Prevalences of polyarteritis
nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and
Churg–Strauss syndrome in a French urban multiethnic population in
2000: a capture-recapture estimate. Arthritis Rheum 2004; 51: 92–99.
6. Keogh KA, Specks U. Churg–Strauss syndrome: clinical presentation,
antineutrophil cytoplasmic antibodies, and leukotriene receptor
antagonists. Am J Med 2003; 115: 284–290.
7. Sable-Fourtassou R, Cohen P, Mahr A et al. Antineutrophil cytoplasmic
antibodies and the Churg–Strauss syndrome. Ann Intern Med 2005; 143:
632–638.
8. Sinico RA, Di Toma L, Maggiore U et al. Prevalence and clinical
significance of antineutrophil cytoplasmic antibodies in Churg–Strauss
syndrome. Arthritis Rheum 2005; 52: 2926–2935.
9. Guillevin L, Cohen P, Gayraud M et al. Churg–Strauss syndrome. Clinical
study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;
78: 26–37.
10. Bacciu A, Bacciu S, Mercante G et al. Ear, nose and throat manifestations
of Churg–Strauss syndrome. Acta Otolaryngol 2006; 126: 503–509.
11. Kim YK, Lee KS, Chung MP et al. Pulmonary involvement in Churg–Strauss
syndrome: an analysis of CT, clinical, and pathologic findings. Eur Radiol
2007; 17: 3157–3165.
12. Cattaneo L, Chierici E, Pavone L et al. Peripheral neuropathy in Wegener’s
granulomatosis, Churg–Strauss syndrome and microscopic polyangiitis.
J Neurol Neurosurg Psychiatry 2007; 78: 1119–1123.
13. Vaglio A, Corradi D, Ronda N et al. Large bowel obstruction heralding
Churg–Strauss syndrome. Am J Gastroenterol 2004; 99: 562–563.
14. Sinico RA, Di Toma L, Maggiore U et al. Renal involvement in
Churg–Strauss syndrome. Am J Kidney Dis 2006; 47: 770–779.
15. Bottero P, Bonini M, Vecchio F et al. The common allergens in the
Churg–Strauss syndrome. Allergy 2007; 62: 1288–1294.
16. Vaglio A, Martorana D, Maggiore U et al. HLA-DRB4 as a genetic
risk factor for Churg–Strauss syndrome. Arthritis Rheum 2007; 56:
3159–3166.
17. Muschen M, Warskulat U, Perniok A et al. Involvement of soluble CD95 in
Churg–Strauss syndrome. Am J Pathol 1999; 155: 915–925.
18. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and
autoimmunity in Churg–Strauss syndrome. Ann NY Acad Sci 2005; 1051:
121–131.
1010 Kidney International (2009) 76, 1006–1011
the rena l consu l t A Vaglio et al.: Churg–Strauss syndrome
19. Corradi D, Vaglio A, Maestri R et al. Eosinophilic myocarditis in a patient
with idiopathic hypereosinophilic syndrome: insights into mechanisms of
myocardial cell death. Hum Pathol 2004; 35: 1160–1163.
20. Polzer K, Karonitsch T, Neumann T et al. Eotaxin-3 is involved in
Churg–Strauss syndrome—a serum marker closely correlating with
disease activity. Rheumatology (Oxford) 2008; 47: 804–808.
21. Pepper RJ, Fabre MA, Pavesio C et al. Rituximab is effective in the treatment
of refractory Churg–Strauss syndrome and is associated with diminished
T-cell interleukin-5 production. Rheumatology (Oxford) 2008; 47: 1104–1105.
22. Cohen P, Pagnoux C, Mahr A et al. Churg–Strauss syndrome with poor-
prognosis factors: a prospective multicenter trial comparing
glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight
patients. Arthritis Rheum 2007; 57: 686–693.
23. Noth I, Strek ME, Leff AR. Churg–Strauss syndrome. Lancet 2003; 361:
587–594.
24. Ribi C, Cohen P, Pagnoux C et al. Treatment of Churg–Strauss syndrome
without poor-prognosis factors: a multicenter, prospective, randomized,
open-label study of seventy-two patients. Arthritis Rheum 2008; 58:
586–594.
25. Bosch X, Guilabert A, Espinosa G et al. Treatment of antineutrophil
cytoplasmic antibody associated vasculitis: a systematic review.
JAMA 2007; 298: 655–669.
Kidney International (2009) 76, 1006–1011 1011
A Vaglio et al.: Churg–Strauss syndrome the rena l consu l t
